Followers | 1078 |
Posts | 80263 |
Boards Moderated | 6 |
Alias Born | 03/10/2009 |
Tuesday, September 19, 2017 8:07:07 PM
Cancer.im Inc. signed an exclusive agreement to commercialize a device that analyzes a small amount of urine for markers that are found in breast and other forms of cancer. This device and the use of biomarkers allow for rapid, point-of-care tests for early screening of cancer that noninvasively monitors levels of pteridine biomarkers in urine. Its unique design delivers superior sensitivity to mass spectrometry at a fraction of the cost of comparable analytical platforms. There are many other advantages to this technology.
STOP & VISIT MY BOARD AT:2011 OTC/PENNY BREAKOUT ALERTS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM